Mindfulness or meditation therapy for Parkinson's disease: A systematic review and meta-analysis of randomized controlled trials.
Study Goal
The researchers aimed to investigate the effects of mindfulness and meditation therapies on Parkinson's disease patients, focusing on motor symptoms, cognitive function, and quality of life.
Results Summary
Mindfulness and meditation therapies significantly improved motor symptoms (UPDRS-Part III) and cognitive function but showed no significant effects on gait velocity, quality of life, activities of daily living, depression, anxiety, pain, or sleep disturbance.
Population
Patients with Parkinson's disease (337 participants across 8 trials).
Effective Dosage
Not specified
Duration
Not specified
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
mindfulness and meditation therapies | decrease | Unified Parkinson's Disease Rating Scale-Part III score | patients with PD | mean difference [MD] = -6.31, 95% confidence interval [95% CI] = -8.57 to -4.05 | significantly improved | #1 |
mindfulness and meditation therapies | increase | cognitive function | patients with PD | standard mean difference [SMD] = 0.62, 95% CI = 0.23 to 1.02 | significantly improved | #2 |
mindfulness therapies | no change | gait velocity | patients with PD | MD = 0.05, 95% CI = -0.23 to 0.34 | no significant differences were discovered | #3 |
mindfulness therapies | no change | Parkinson's Disease Questionnaire-39 Summary Index | patients with PD | MD = 0.51, 95% CI = -1.12 to 2.14 | no significant differences were discovered | #4 |
mindfulness therapies | no change | activities of daily living | patients with PD | SMD = -1.65, 95% CI = -3.74 to 0.45 | no significant differences were discovered | #5 |
mindfulness therapies | no change | depression | patients with PD | SMD = -0.43, 95% CI = -0.97 to 0.11 | no significant differences were discovered | #6 |
mindfulness therapies | no change | anxiety | patients with PD | SMD = -0.80, 95% CI = -1.78 to 0.19 | no significant differences were discovered | #7 |
mindfulness therapies | no change | pain | patients with PD | SMD = 0.79, 95% CI = -1.06 to 2.63 | no significant differences were discovered | #8 |
mindfulness therapies | no change | sleep disturbance | patients with PD | SMD = -0.67, 95% CI = -1.58 to 0.24 | no significant differences were discovered | #9 |
BACKGROUND: Parkinson's disease (PD) is the second most common neurodegenerative disorder worldwide. Mindfulness and meditation therapies have been demonstrated as effective alternative treatments for patients with neurological disorders. However, the effects of mindfulness and meditation therapies on PD remain unclear. This meta-analysis investigated the effects of mindfulness and meditation therapies in PD patients. METHODS: A literature search was conducted using PubMed, Embase, Cochrane Library, and ClinicalTrials.gov for randomized controlled trials comparing mindfulness and meditation therapies with control treatments in patients with PD. RESULTS: Nine articles involving eight trials were included, with a total of 337 patients. Our meta-analysis revealed that mindfulness and meditation therapies significantly improved Unified Parkinson's Disease Rating Scale-Part III score (mean difference [MD] = -6.31, 95% confidence interval [95% CI] = -8.57 to -4.05) and cognitive function (standard mean difference [SMD] = 0.62, 95% CI = 0.23 to 1.02). However, no significant differences were discovered between mindfulness therapies and control in gait velocity (MD = 0.05, 95% CI = -0.23 to 0.34), Parkinson's Disease Questionnaire-39 Summary Index (MD = 0.51, 95% CI = -1.12 to 2.14), activities of daily living (SMD = -1.65, 95% CI = -3.74 to 0.45), depression (SMD = -0.43, 95% CI = -0.97 to 0.11), anxiety (SMD = -0.80, 95% CI = -1.78 to 0.19), pain (SMD = 0.79, 95% CI = -1.06 to 2.63), or sleep disturbance (SMD = -0.67, 95% CI = -1.58 to 0.24). CONCLUSION: Mindfulness and meditation therapies may serve as complementary and alternative treatments for PD patients.